{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:30:51Z","timestamp":1771662651777,"version":"3.50.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270212"],"award-info":[{"award-number":["82270212"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY20H080003"],"award-info":[{"award-number":["LY20H080003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["Y20220716"],"award-info":[{"award-number":["Y20220716"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Discipline Cluster of Oncology, Wenzhou Medical University","award":["z2-2023023"],"award-info":[{"award-number":["z2-2023023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02572-w","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:38:26Z","timestamp":1748666306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of a cuproptosis-related prognostic signature to reveal heterogeneity of the immune microenvironment and drug sensitivity in acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"30","author":[{"given":"Bingxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuxia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sisi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhili","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enqing","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luning","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansen","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanru","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhouxiang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songfu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongyong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"issue":"2","key":"2572_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/leu.2009.252","volume":"24","author":"CH Pui","year":"2010","unstructured":"Pui CH, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):371\u201382.","journal-title":"Leukemia"},{"issue":"10230","key":"2572_CR2","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146\u201362.","journal-title":"Lancet"},{"issue":"9","key":"2572_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJM199808273390907","volume":"339","author":"CH Pui","year":"1998","unstructured":"Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339(9):605\u201315.","journal-title":"N Engl J Med"},{"issue":"3","key":"2572_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","volume":"50","author":"CH Pui","year":"2013","unstructured":"Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3):185\u201396.","journal-title":"Semin Hematol"},{"issue":"14","key":"2572_CR5","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. J Clin Oncol. 2012;30(14):1663\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2572_CR6","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3390\/jcm10091926","volume":"10","author":"H Inaba","year":"2021","unstructured":"Inaba H, Pui CH. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J Clin Med. 2021;10(9):1926.","journal-title":"J Clin Med"},{"key":"2572_CR7","unstructured":"Silva JJRFd, Williams RJP, The biological chemistry of the elements : the inorganic chemistry of life. 2nd ed. 2001, Oxford: Oxford University Press. xvii, 575 p."},{"issue":"5","key":"2572_CR8","doi-asserted-by":"publisher","first-page":"797S","DOI":"10.1093\/ajcn\/63.5.797","volume":"63","author":"MC Linder","year":"1996","unstructured":"Linder MC, Hazegh-Azam M. Copper biochemistry and molecular biology. Am J Clin Nutr. 1996;63(5):797S-811S.","journal-title":"Am J Clin Nutr"},{"issue":"5 Suppl","key":"2572_CR9","doi-asserted-by":"publisher","first-page":"996S","DOI":"10.1093\/ajcn\/67.5.996S","volume":"67","author":"RB Rucker","year":"1998","unstructured":"Rucker RB, et al. Copper, lysyl oxidase, and extracellular matrix protein cross-linking. Am J Clin Nutr. 1998;67(5 Suppl):996S-1002S.","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"2572_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1152\/physrev.00004.2006","volume":"87","author":"S Lutsenko","year":"2007","unstructured":"Lutsenko S, et al. Function and regulation of human copper-transporting ATPases. Physiol Rev. 2007;87(3):1011\u201346.","journal-title":"Physiol Rev"},{"issue":"15","key":"2572_CR11","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s00018-010-0330-x","volume":"67","author":"L Banci","year":"2010","unstructured":"Banci L, et al. Cellular copper distribution: a mechanistic systems biology approach. Cell Mol Life Sci. 2010;67(15):2563\u201389.","journal-title":"Cell Mol Life Sci"},{"issue":"1\u20132","key":"2572_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.mrfmmm.2012.03.010","volume":"733","author":"MC Linder","year":"2012","unstructured":"Linder MC. The relationship of copper to DNA damage and damage prevention in humans. Mutat Res. 2012;733(1\u20132):83\u201391.","journal-title":"Mutat Res"},{"issue":"19","key":"2572_CR13","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1158\/0008-5472.CAN-20-0471","volume":"80","author":"F Voli","year":"2020","unstructured":"Voli F, et al. Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion. Cancer Res. 2020;80(19):4129\u201344.","journal-title":"Cancer Res"},{"issue":"1\u20133","key":"2572_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1385\/BTER:114:1:41","volume":"114","author":"XL Zuo","year":"2006","unstructured":"Zuo XL, et al. Levels of selenium, zinc, copper, and antioxidant enzyme activity in patients with leukemia. Biol Trace Elem Res. 2006;114(1\u20133):41\u201353.","journal-title":"Biol Trace Elem Res"},{"key":"2572_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.711227","volume":"8","author":"LM Ruiz","year":"2021","unstructured":"Ruiz LM, Libedinsky A, Elorza AA. Role of copper on mitochondrial function and metabolism. Front Mol Biosci. 2021;8: 711227.","journal-title":"Front Mol Biosci"},{"key":"2572_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ajh.2830030209","volume":"3","author":"BL Zidar","year":"1977","unstructured":"Zidar BL, et al. Observations on the anemia and neutropenia of human copper deficiency. Am J Hematol. 1977;3:177\u201385.","journal-title":"Am J Hematol"},{"issue":"4","key":"2572_CR17","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1182\/blood-2002-01-0256","volume":"100","author":"XT Gregg","year":"2002","unstructured":"Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood. 2002;100(4):1493\u20135.","journal-title":"Blood"},{"issue":"6","key":"2572_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1600-0609.2008.01050.x","volume":"80","author":"TR Halfdanarson","year":"2008","unstructured":"Halfdanarson TR, et al. Hematological manifestations of copper deficiency: a retrospective review. Eur J Haematol. 2008;80(6):523\u201331.","journal-title":"Eur J Haematol"},{"issue":"6586","key":"2572_CR19","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254\u201361.","journal-title":"Science"},{"key":"2572_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.919231","volume":"13","author":"M Yang","year":"2022","unstructured":"Yang M, et al. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA. Front Immunol. 2022;13: 919231.","journal-title":"Front Immunol"},{"key":"2572_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.986214","volume":"13","author":"JY Liu","year":"2022","unstructured":"Liu JY, et al. The role of cuproptosis-related gene in the classification and prognosis of melanoma. Front Immunol. 2022;13: 986214.","journal-title":"Front Immunol"},{"key":"2572_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.997573","volume":"13","author":"S Zhang","year":"2022","unstructured":"Zhang S, et al. Revealing prognostic and tumor microenvironment characteristics of cuproptosis in bladder cancer by genomic analysis. Front Genet. 2022;13: 997573.","journal-title":"Front Genet"},{"key":"2572_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.957966","volume":"12","author":"A Feng","year":"2022","unstructured":"Feng A, et al. A novel cuproptosis-related lncRNA nomogram to improve the prognosis prediction of gastric cancer. Front Oncol. 2022;12: 957966.","journal-title":"Front Oncol"},{"issue":"D1","key":"2572_CR24","doi-asserted-by":"publisher","first-page":"D900","DOI":"10.1093\/nar\/gky939","volume":"47","author":"H Yuan","year":"2019","unstructured":"Yuan H, et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 2019;47(D1):D900\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2572_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ccell.2018.01.006","volume":"33","author":"CAG Booth","year":"2018","unstructured":"Booth CAG, et al. Ezh2 and Runx1 mutations collaborate to initiate lympho-myeloid leukemia in early thymic progenitors. Cancer Cell. 2018;33(2):274-291.e8.","journal-title":"Cancer Cell"},{"issue":"6","key":"2572_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.ccell.2016.11.002","volume":"30","author":"S Ebinger","year":"2016","unstructured":"Ebinger S, et al. Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia. Cancer Cell. 2016;30(6):849\u201362.","journal-title":"Cancer Cell"},{"issue":"12","key":"2572_CR27","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572\u20133.","journal-title":"Bioinformatics"},{"key":"2572_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.csda.2021.107190","volume":"158","author":"F Batool","year":"2021","unstructured":"Batool F, Hennig C. Clustering with the average silhouette width. Comput Stat Data Anal. 2021;158:18.","journal-title":"Comput Stat Data Anal"},{"key":"2572_CR29","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1038\/srep06207","volume":"4","author":"Y Senbabaoglu","year":"2014","unstructured":"Senbabaoglu Y, Michailidis G, Li JZ. Critical limitations of consensus clustering in class discovery. Sci Rep. 2014;4:6207.","journal-title":"Sci Rep"},{"issue":"5","key":"2572_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"issue":"43","key":"2572_CR31","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2572_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.","journal-title":"Genome Biol"},{"issue":"2","key":"2572_CR33","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","volume":"173","author":"TM Malta","year":"2018","unstructured":"Malta TM, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338-354.e15.","journal-title":"Cell"},{"issue":"10","key":"2572_CR34","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"issue":"8","key":"2572_CR35","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340.","journal-title":"J Clin Invest"},{"issue":"1","key":"2572_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248\u201362.","journal-title":"Cell Rep"},{"issue":"2","key":"2572_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello SM, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020;1(2):235\u201348.","journal-title":"Nat Cancer"},{"issue":"2","key":"2572_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nchembio.1986","volume":"12","author":"MG Rees","year":"2016","unstructured":"Rees MG, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12(2):109\u201316.","journal-title":"Nat Chem Biol"},{"key":"2572_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa164","author":"C Yang","year":"2021","unstructured":"Yang C, et al. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology. Brief Bioinform. 2021. https:\/\/doi.org\/10.1093\/bib\/bbaa164.","journal-title":"Brief Bioinform"},{"key":"2572_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa295","author":"C Yang","year":"2021","unstructured":"Yang C, et al. Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen. Brief Bioinform. 2021. https:\/\/doi.org\/10.1093\/bib\/bbaa295.","journal-title":"Brief Bioinform"},{"issue":"15","key":"2572_CR41","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1002\/cmdc.202100172","volume":"16","author":"F Michniewicz","year":"2021","unstructured":"Michniewicz F, et al. Copper: an intracellular achilles\u2019 heel allowing the targeting of epigenetics, kinase pathways, and cell metabolism in cancer therapeutics. ChemMedChem. 2021;16(15):2315\u201329.","journal-title":"ChemMedChem"},{"issue":"9","key":"2572_CR42","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1002\/iub.2341","volume":"72","author":"Y Li","year":"2020","unstructured":"Li Y. Copper homeostasis: emerging target for cancer treatment. IUBMB Life. 2020;72(9):1900\u20138.","journal-title":"IUBMB Life"},{"issue":"1","key":"2572_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ctrv.2008.07.004","volume":"35","author":"A Gupte","year":"2009","unstructured":"Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev. 2009;35(1):32\u201346.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2572_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10534-008-9174-3","volume":"22","author":"S Majumder","year":"2009","unstructured":"Majumder S, et al. The role of copper in drug-resistant murine and human tumors. Biometals. 2009;22(2):377\u201384.","journal-title":"Biometals"},{"issue":"2","key":"2572_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1677\/erc.0.0110255","volume":"11","author":"VL Goodman","year":"2004","unstructured":"Goodman VL, Brewer GJ, Merajver SD. Copper deficiency as an anti-cancer strategy. Endocr Relat Cancer. 2004;11(2):255\u201363.","journal-title":"Endocr Relat Cancer"},{"issue":"7501","key":"2572_CR46","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nature13180","volume":"509","author":"DC Brady","year":"2014","unstructured":"Brady DC, et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature. 2014;509(7501):492\u20136.","journal-title":"Nature"},{"key":"2572_CR47","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jtemb.2019.06.008","volume":"55","author":"A De Luca","year":"2019","unstructured":"De Luca A, et al. Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy. J Trace Elem Med Biol. 2019;55:204\u201313.","journal-title":"J Trace Elem Med Biol"},{"issue":"14","key":"2572_CR48","doi-asserted-by":"publisher","first-page":"6836","DOI":"10.1073\/pnas.1817473116","volume":"116","author":"V Shanbhag","year":"2019","unstructured":"Shanbhag V, et al. ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis. Proc Natl Acad Sci U S A. 2019;116(14):6836\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"34","key":"2572_CR49","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1038\/sj.onc.1209606","volume":"25","author":"M Fontenay","year":"2006","unstructured":"Fontenay M, et al. Mitochondria in hematopoiesis and hematological diseases. Oncogene. 2006;25(34):4757\u201367.","journal-title":"Oncogene"},{"issue":"3","key":"2572_CR50","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/MOH.0b013e328351c48b","volume":"19","author":"J Chung","year":"2012","unstructured":"Chung J, Chen C, Paw BH. Heme metabolism and erythropoiesis. Curr Opin Hematol. 2012;19(3):156\u201362.","journal-title":"Curr Opin Hematol"},{"issue":"10","key":"2572_CR51","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.exphem.2005.06.015","volume":"33","author":"T Peled","year":"2005","unstructured":"Peled T, et al. Chelatable cellular copper modulates differentiation and self-renewal of cord blood-derived hematopoietic progenitor cells. Exp Hematol. 2005;33(10):1092\u2013100.","journal-title":"Exp Hematol"},{"issue":"23","key":"2572_CR52","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1182\/blood-2011-01-283606","volume":"117","author":"A Dahlberg","year":"2011","unstructured":"Dahlberg A, Delaney C, Bernstein ID. Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood. 2011;117(23):6083\u201390.","journal-title":"Blood"},{"issue":"15","key":"2572_CR53","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.18632\/oncotarget.2027","volume":"5","author":"R Bortolozzi","year":"2014","unstructured":"Bortolozzi R, et al. A novel copper(I) complex induces ER-stress-mediated apoptosis and sensitizes B-acute lymphoblastic leukemia cells to chemotherapeutic agents. Oncotarget. 2014;5(15):5978\u201391.","journal-title":"Oncotarget"},{"key":"2572_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.freeradbiomed.2013.02.003","volume":"60","author":"K Lee","year":"2013","unstructured":"Lee K, et al. The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies. Free Radic Biol Med. 2013;60:157\u201367.","journal-title":"Free Radic Biol Med"},{"key":"2572_CR55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.biopha.2016.08.056","volume":"84","author":"K Banerjee","year":"2016","unstructured":"Banerjee K, et al. A copper chelate induces apoptosis and overcomes multidrug resistance in T-cell acute lymphoblastic leukemia through redox imbalance and inhibition of EGFR\/PI3K\/Akt expression. Biomed Pharmacother. 2016;84:71\u201392.","journal-title":"Biomed Pharmacother"},{"issue":"27","key":"2572_CR56","doi-asserted-by":"publisher","first-page":"6914","DOI":"10.1021\/jm049568z","volume":"47","author":"D Cen","year":"2004","unstructured":"Cen D, et al. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem. 2004;47(27):6914\u201320.","journal-title":"J Med Chem"},{"issue":"9","key":"2572_CR57","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/bjc.2012.442","volume":"107","author":"P Liu","year":"2012","unstructured":"Liu P, et al. Cytotoxic effect of disulfiram\/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer. 2012;107(9):1488\u201397.","journal-title":"Br J Cancer"},{"issue":"9","key":"2572_CR58","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/ijc.27482","volume":"131","author":"C Conticello","year":"2012","unstructured":"Conticello C, et al. Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. Int J Cancer. 2012;131(9):2197\u2013203.","journal-title":"Int J Cancer"},{"issue":"50","key":"2572_CR59","doi-asserted-by":"publisher","first-page":"82200","DOI":"10.18632\/oncotarget.9413","volume":"7","author":"M Deng","year":"2016","unstructured":"Deng M, et al. Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram\/copper complex in vitro and in vivo in patient-derived xenograft models. Oncotarget. 2016;7(50):82200\u201312.","journal-title":"Oncotarget"},{"key":"2572_CR60","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1479-5876-12-163","volume":"12","author":"J Zha","year":"2014","unstructured":"Zha J, et al. Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition. J Transl Med. 2014;12:163.","journal-title":"J Transl Med"},{"issue":"4","key":"2572_CR61","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bcmd.2011.08.004","volume":"47","author":"B Xu","year":"2011","unstructured":"Xu B, et al. Disulfiram\/copper complex activated JNK\/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells. Blood Cells Mol Dis. 2011;47(4):264\u20139.","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"2572_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.176","volume":"8","author":"B Xu","year":"2017","unstructured":"Xu B, et al. Disulfiram\/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-kappaB and Nrf2. Cell Death Dis. 2017;8(5): e2797.","journal-title":"Cell Death Dis"},{"issue":"6","key":"2572_CR63","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/leu.2016.26","volume":"30","author":"NM Anderson","year":"2016","unstructured":"Anderson NM, et al. The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis. Leukemia. 2016;30(6):1365\u201374.","journal-title":"Leukemia"},{"issue":"4","key":"2572_CR64","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood.2021013201","volume":"139","author":"ML Amaya","year":"2022","unstructured":"Amaya ML, et al. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022;139(4):584\u201396.","journal-title":"Blood"},{"issue":"1","key":"2572_CR65","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/genes12010079","volume":"12","author":"C Gonzalez-Gil","year":"2021","unstructured":"Gonzalez-Gil C, et al. The Yin and Yang-like clinical implications of the CDKN2A\/ARF\/CDKN2B Gene cluster in acute lymphoblastic leukemia. Genes (Basel). 2021;12(1):79.","journal-title":"Genes (Basel)"},{"issue":"1","key":"2572_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/07853890.2018.1564359","volume":"51","author":"W Zhang","year":"2019","unstructured":"Zhang W, Kuang P, Liu T. Prognostic significance of CDKN2A\/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Ann Med. 2019;51(1):28\u201340.","journal-title":"Ann Med"},{"issue":"17","key":"2572_CR67","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","volume":"17","author":"FJ Stott","year":"1998","unstructured":"Stott FJ, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17(17):5001\u201314.","journal-title":"EMBO J"},{"issue":"4","key":"2572_CR68","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","volume":"22","author":"CM Sawai","year":"2012","unstructured":"Sawai CM, et al. Therapeutic targeting of the cyclin D3:CDK4\/6 complex in T cell leukemia. Cancer Cell. 2012;22(4):452\u201365.","journal-title":"Cancer Cell"},{"issue":"19","key":"2572_CR69","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1158\/1078-0432.CCR-13-0259","volume":"19","author":"KE Sheppard","year":"2013","unstructured":"Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013;19(19):5320\u20138.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2572_CR70","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1158\/1078-0432.CCR-13-1551","volume":"20","author":"MA Dickson","year":"2014","unstructured":"Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res. 2014;20(13):3379\u201383.","journal-title":"Clin Cancer Res"},{"issue":"30","key":"2572_CR71","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.2174\/092986708786848479","volume":"15","author":"T Furukawa","year":"2008","unstructured":"Furukawa T, et al. Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem. 2008;15(30):3268\u201378.","journal-title":"Curr Med Chem"},{"issue":"6","key":"2572_CR72","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/ph14060549","volume":"14","author":"MT Kuo","year":"2021","unstructured":"Kuo MT, et al. Targeting the copper transport system to improve treatment efficacies of platinum-containing drugs in cancer chemotherapy. Pharmaceuticals (Basel). 2021;14(6):549.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"2572_CR73","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1055\/s-2008-1066611","volume":"114","author":"JP Sieb","year":"1989","unstructured":"Sieb JP, Mattle H, Pirovino M. Neurofibrosarcomas in neurofibromatosis 1. Dtsch Med Wochenschr. 1989;114(11):417\u20139.","journal-title":"Dtsch Med Wochenschr"},{"issue":"4","key":"2572_CR74","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/ped.12313","volume":"56","author":"S Maeda","year":"2014","unstructured":"Maeda S, et al. Acute lymphoblastic leukemia in a girl with Wilson\u2019s disease. Pediatr Int. 2014;56(4):626\u20139.","journal-title":"Pediatr Int"},{"key":"2572_CR75","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev.nu.15.070195.001025","volume":"15","author":"NP Curthoys","year":"1995","unstructured":"Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr. 1995;15:133\u201359.","journal-title":"Annu Rev Nutr"},{"issue":"7239","key":"2572_CR76","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature07823","volume":"458","author":"P Gao","year":"2009","unstructured":"Gao P, et al. c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762\u20135.","journal-title":"Nature"},{"issue":"4","key":"2572_CR77","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1073\/pnas.1112495109","volume":"109","author":"A Cassago","year":"2012","unstructured":"Cassago A, et al. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc Natl Acad Sci U S A. 2012;109(4):1092\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2572_CR78","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2010.08.009","volume":"18","author":"JB Wang","year":"2010","unstructured":"Wang JB, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18(3):207\u201319.","journal-title":"Cancer Cell"},{"issue":"11","key":"2572_CR79","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","volume":"126","author":"N Jacque","year":"2015","unstructured":"Jacque N, et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood. 2015;126(11):1346\u201356.","journal-title":"Blood"},{"issue":"4","key":"2572_CR80","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","volume":"13","author":"MI Gross","year":"2014","unstructured":"Gross MI, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13(4):890\u2013901.","journal-title":"Mol Cancer Ther"},{"issue":"38","key":"2572_CR81","doi-asserted-by":"publisher","first-page":"26533","DOI":"10.1074\/jbc.M114.593970","volume":"289","author":"J Fan","year":"2014","unstructured":"Fan J, et al. Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect. J Biol Chem. 2014;289(38):26533\u201341.","journal-title":"J Biol Chem"},{"issue":"6","key":"2572_CR82","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1158\/1078-0432.CCR-14-2146","volume":"21","author":"F Alvarez-Calderon","year":"2015","unstructured":"Alvarez-Calderon F, et al. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res. 2015;21(6):1360\u201372.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2572_CR83","doi-asserted-by":"publisher","first-page":"19392","DOI":"10.1038\/s41598-024-70245-5","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. NMN partially rescues cuproptosis by upregulating sirt2 to increase intracellular NADPH. Sci Rep. 2024;14(1):19392.","journal-title":"Sci Rep"},{"issue":"11","key":"2572_CR84","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1182\/blood.2024026085","volume":"145","author":"CS Escherich","year":"2025","unstructured":"Escherich CS, et al. DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood. 2025;145(11):1182\u201394.","journal-title":"Blood"},{"issue":"2","key":"2572_CR85","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41375-024-02451-z","volume":"39","author":"X Li","year":"2025","unstructured":"Li X, et al. YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1\/me3 epigenetic axis. Leukemia. 2025;39(2):308\u201322.","journal-title":"Leukemia"},{"key":"2572_CR86","doi-asserted-by":"crossref","unstructured":"Yang Z, et al. Hypoxia inducible factor-1alpha drives cancer resistance to cuproptosis. Cancer Cell, 2025.","DOI":"10.1016\/j.ccell.2025.02.015"},{"issue":"4","key":"2572_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110752","volume":"39","author":"V Morris","year":"2022","unstructured":"Morris V, et al. Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells. Cell Rep. 2022;39(4): 110752.","journal-title":"Cell Rep"},{"issue":"21","key":"2572_CR88","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1093\/nar\/25.21.4173","volume":"25","author":"TR Burglin","year":"1997","unstructured":"Burglin TR. Analysis of TALE superclass homeobox genes (MEIS, PBC, KNOX, Iroquois, TGIF) reveals a novel domain conserved between plants and animals. Nucleic Acids Res. 1997;25(21):4173\u201380.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"2572_CR89","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1182\/blood-2011-10-382861","volume":"119","author":"H Kang","year":"2012","unstructured":"Kang H, et al. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Blood. 2012;119(8):1872\u201381.","journal-title":"Blood"},{"issue":"1","key":"2572_CR90","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12920-021-00975-2","volume":"14","author":"L Shi","year":"2021","unstructured":"Shi L, Huang R, Lai Y. Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemia. BMC Med Genomics. 2021;14(1):127.","journal-title":"BMC Med Genomics"},{"key":"2572_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.679584","volume":"8","author":"C Faoro","year":"2021","unstructured":"Faoro C, Ataide SF. Noncanonical functions and cellular dynamics of the mammalian signal recognition particle components. Front Mol Biosci. 2021;8: 679584.","journal-title":"Front Mol Biosci"},{"issue":"6","key":"2572_CR92","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/onc.2012.93","volume":"32","author":"V Stresing","year":"2013","unstructured":"Stresing V, et al. Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene. 2013;32(6):724\u201335.","journal-title":"Oncogene"},{"issue":"24","key":"2572_CR93","doi-asserted-by":"publisher","first-page":"18266","DOI":"10.1074\/jbc.275.24.18266","volume":"275","author":"H Kim","year":"2000","unstructured":"Kim H, et al. Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J Biol Chem. 2000;275(24):18266\u201370.","journal-title":"J Biol Chem"},{"issue":"24","key":"2572_CR94","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1182\/blood-2017-10-813139","volume":"131","author":"M Ying","year":"2018","unstructured":"Ying M, et al. Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood. 2018;131(24):2698\u2013711.","journal-title":"Blood"},{"issue":"11","key":"2572_CR95","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.neo.2018.08.013","volume":"20","author":"R Bera","year":"2018","unstructured":"Bera R, et al. Genetic and epigenetic perturbations by DNMT3A-R882 mutants impaired apoptosis through augmentation of PRDX2 in myeloid leukemia cells. Neoplasia. 2018;20(11):1106\u201320.","journal-title":"Neoplasia"},{"issue":"7","key":"2572_CR96","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/annonc\/mdp569","volume":"21","author":"RJ Li","year":"2010","unstructured":"Li RJ, et al. Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance. Ann Oncol. 2010;21(7):1506\u201314.","journal-title":"Ann Oncol"},{"issue":"1","key":"2572_CR97","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/ng.1020","volume":"44","author":"C Wu","year":"2011","unstructured":"Wu C, et al. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet. 2011;44(1):62\u20136.","journal-title":"Nat Genet"},{"issue":"5","key":"2572_CR98","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359.","journal-title":"N Engl J Med"},{"issue":"24","key":"2572_CR99","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1182\/blood-2015-01-567842","volume":"125","author":"M Muschen","year":"2015","unstructured":"Muschen M. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood. 2015;125(24):3688\u201393.","journal-title":"Blood"},{"issue":"23","key":"2572_CR100","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1200\/JCO.2017.72.6745","volume":"35","author":"JP Leonard","year":"2017","unstructured":"Leonard JP, Martin P, Roboz GJ. Practical Implications of the 2016 revision of the World Health organization classification of lymphoid and myeloid neoplasms and acute leukemia. J Clin Oncol. 2017;35(23):2708\u201315.","journal-title":"J Clin Oncol"},{"key":"2572_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.841814","volume":"9","author":"V Oliveri","year":"2022","unstructured":"Oliveri V. Selective targeting of cancer cells by copper ionophores: an overview. Front Mol Biosci. 2022;9: 841814.","journal-title":"Front Mol Biosci"},{"issue":"12","key":"2572_CR102","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3324\/haematol.2013.092411","volume":"98","author":"D Niewerth","year":"2013","unstructured":"Niewerth D, et al. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica. 2013;98(12):1896\u2013904.","journal-title":"Haematologica"},{"issue":"1","key":"2572_CR103","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-024-01604-y","volume":"17","author":"D Sedloev","year":"2024","unstructured":"Sedloev D, et al. Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia. J Hematol Oncol. 2024;17(1):85.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2572_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29999","volume":"69","author":"MJ Burke","year":"2022","unstructured":"Burke MJ, et al. Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed\/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022;69(12): e29999.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2572_CR105","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3109\/10428194.2015.1076930","volume":"57","author":"LD Wartman","year":"2016","unstructured":"Wartman LD, et al. A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57(3):728\u201330.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2572_CR106","doi-asserted-by":"publisher","first-page":"E114","DOI":"10.1002\/ajh.26105","volume":"96","author":"BA Jonas","year":"2021","unstructured":"Jonas BA, et al. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2021;96(4):E114\u20137.","journal-title":"Am J Hematol"},{"issue":"3","key":"2572_CR107","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","volume":"26","author":"MM Mita","year":"2008","unstructured":"Mita MM, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008;26(3):361\u20137.","journal-title":"J Clin Oncol"},{"issue":"17","key":"2572_CR108","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2021015106","volume":"140","author":"S Laukkanen","year":"2022","unstructured":"Laukkanen S, et al. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. Blood. 2022;140(17):1891\u2013906.","journal-title":"Blood"},{"issue":"9","key":"2572_CR109","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","volume":"14","author":"DA Rizzieri","year":"2008","unstructured":"Rizzieri DA, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008;14(9):2756\u201362.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2572_CR110","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1158\/1535-7163.MCT-18-0706","volume":"18","author":"S Kannan","year":"2019","unstructured":"Kannan S, et al. Antileukemia effects of notch-mediated inhibition of oncogenic PLK1 in B-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2019;18(9):1615\u201327.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2572_CR111","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4161\/cbt.19074","volume":"13","author":"C Didier","year":"2012","unstructured":"Didier C, et al. Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype. Cancer Biol Ther. 2012;13(5):307\u201313.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2572_CR112","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00018-024-05340-x","volume":"81","author":"V Petrova","year":"2024","unstructured":"Petrova V, et al. Identification of novel neuroprotectants against vincristine-induced neurotoxicity in iPSC-derived neurons. Cell Mol Life Sci. 2024;81(1):315.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2572_CR113","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/leu.2017.282","volume":"32","author":"M Waibel","year":"2018","unstructured":"Waibel M, et al. Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia. Leukemia. 2018;32(1):237\u201341.","journal-title":"Leukemia"},{"issue":"1","key":"2572_CR114","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/2643-3230.BCD-20-0093","volume":"2","author":"V Cordo","year":"2021","unstructured":"Cordo V, et al. T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies. Blood Cancer Discov. 2021;2(1):19\u201331.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2572_CR115","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/leu.2015.222","volume":"30","author":"K Akahane","year":"2016","unstructured":"Akahane K, et al. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia. 2016;30(1):219\u201328.","journal-title":"Leukemia"},{"issue":"14","key":"2572_CR116","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2008-08-173369","volume":"113","author":"A Nahimana","year":"2009","unstructured":"Nahimana A, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood. 2009;113(14):3276\u201386.","journal-title":"Blood"},{"issue":"17","key":"2572_CR117","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-14-3023","volume":"21","author":"A Cagnetta","year":"2015","unstructured":"Cagnetta A, et al. APO866 increases antitumor activity of cyclosporin-a by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells. Clin Cancer Res. 2015;21(17):3934\u201345.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2572_CR118","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s00277-016-2766-z","volume":"95","author":"X Liu","year":"2016","unstructured":"Liu X, et al. Baicalein suppresses the proliferation of acute T-lymphoblastic leukemia Jurkat cells by inhibiting the Wnt\/beta-catenin signaling. Ann Hematol. 2016;95(11):1787\u201393.","journal-title":"Ann Hematol"},{"issue":"2","key":"2572_CR119","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.intimp.2014.10.005","volume":"23","author":"B Orzechowska","year":"2014","unstructured":"Orzechowska B, et al. Baicalin from the extract of Scutellaria baicalensis affects the innate immunity and apoptosis in leukocytes of children with acute lymphocytic leukemia. Int Immunopharmacol. 2014;23(2):558\u201367.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"2572_CR120","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/gcc.22880","volume":"59","author":"N Jin","year":"2020","unstructured":"Jin N, et al. Chromosomal instability upregulates interferon in acute myeloid leukemia. Genes Chromosomes Cancer. 2020;59(11):627\u201338.","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"2572_CR121","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1042\/BCJ20170164","volume":"475","author":"EM De Francesco","year":"2018","unstructured":"De Francesco EM, Sotgia F, Lisanti MP. Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. Biochem J. 2018;475(9):1611\u201334.","journal-title":"Biochem J"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02572-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02572-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02572-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T06:02:16Z","timestamp":1748671336000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02572-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2572"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02572-w","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee in Clinical Research of the First Affiliated Hospital of Wenzhou Medical University (protocol code 2021-063), and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients in this study provided their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"435"}}